Helixate FS: Full Drug Profile

Helixate FS - General Information

Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells

Pharmacology of Helixate FS

Helixate FS binds factor IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade.

Helixate FS for patients

Helixate FS Interactions

Helixate FS Contraindications

Known hypersensitivity to mouse protein is a contraindication to the use of Antihemophilic Factor (Human) (AHF), Hemofil M, Method M, Monoclonal Purified.

Additional information about Helixate FS

Helixate FS Indication: For the treatment of hemophilia A, von Willebrand diseae and Factor XIII deficiency Mechanism Of Action: Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia). Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Antihemophilic Factor Synonyms: AHF; Coagulation factor VIII precursor; Procoagulant component Drug Category: Coagulants; Thrombotic Agents Drug Type: Biotech; Approved; Investigational Other Brand Names containing Antihemophilic Factor: Advate; Alphanate; Bioclate; Helixate; Helixate FS; Hemofil M; Humate-P; Hyate:C; Koate-HP; Kogenate; Kogenate FS; Monarc-M; Monoclate-P; Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: 8.4-19.3 hrs Dosage Forms of Helixate FS: Powder, for solution Intravenous Chemical IUPAC Name: Not Available Chemical Formula: C11794H18314N3220O3553S83 Antihemophilic Factor on Wikipedia: https://en.wikipedia.org/wiki/Antihemophilic_Factor Organisms Affected: Humans and other mammals